Trial Outcomes & Findings for Low-Dose Atropine for Treatment of Myopia (NCT NCT03334253)

Last Updated: 2026-07-31

Results Overview

The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

200 participants

Primary outcome timeframe

At 24 months

Results posted on

2026-07-31

Participant Flow

Two hundred patients were enrolled into the run-in phase; 13 were ineligible for randomization

Participant milestones

Participant milestones
Measure	Atropine Group 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Overall Study STARTED	125	62
Overall Study COMPLETED	118	57
Overall Study NOT COMPLETED	7	5

Reasons for withdrawal

Reasons for withdrawal
Measure	Atropine Group 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Overall Study Withdrawal by Subject	1	0
Overall Study Lost to Follow-up	4	3
Overall Study Moved residence	2	2

Baseline Characteristics

Flat corneal radius was not available for 1 patient in the placebo group.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo Group n=62 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops	Total n=187 Participants Total of all reporting groups	Atropine Group n=125 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops
Age, Continuous	10.1 years STANDARD_DEVIATION 1.8 • n=62 Participants	10.1 years STANDARD_DEVIATION 1.8 • n=187 Participants	10.1 years STANDARD_DEVIATION 1.8 • n=125 Participants
Age, Customized 5 to <7 years	3 Participants n=62 Participants	9 Participants n=187 Participants	6 Participants n=125 Participants
Age, Customized 7 to <9 years	13 Participants n=62 Participants	41 Participants n=187 Participants	28 Participants n=125 Participants
Age, Customized 9 to <11 years	20 Participants n=62 Participants	70 Participants n=187 Participants	50 Participants n=125 Participants
Age, Customized 11 to <13 years	26 Participants n=62 Participants	67 Participants n=187 Participants	41 Participants n=125 Participants
Sex: Female, Male Female	36 Participants n=62 Participants	101 Participants n=187 Participants	65 Participants n=125 Participants
Sex: Female, Male Male	26 Participants n=62 Participants	86 Participants n=187 Participants	60 Participants n=125 Participants
Race/Ethnicity, Customized White (not Hispanic or Latino)	28 Participants n=62 Participants	86 Participants n=187 Participants	58 Participants n=125 Participants
Race/Ethnicity, Customized White Hispanic or Latino	9 Participants n=62 Participants	30 Participants n=187 Participants	21 Participants n=125 Participants
Race/Ethnicity, Customized Black	14 Participants n=62 Participants	34 Participants n=187 Participants	20 Participants n=125 Participants
Race/Ethnicity, Customized East Asian	4 Participants n=62 Participants	20 Participants n=187 Participants	16 Participants n=125 Participants
Race/Ethnicity, Customized West Asian / South Asian	2 Participants n=62 Participants	6 Participants n=187 Participants	4 Participants n=125 Participants
Race/Ethnicity, Customized More Than one race	5 Participants n=62 Participants	11 Participants n=187 Participants	6 Participants n=125 Participants
Eye Color Brown	41 Participants n=62 Participants	123 Participants n=187 Participants	82 Participants n=125 Participants
Eye Color Not Brown	21 Participants n=62 Participants	64 Participants n=187 Participants	43 Participants n=125 Participants
Number of Biological Parents with Myopia 0	11 Participants n=62 Participants	27 Participants n=187 Participants	16 Participants n=125 Participants
Number of Biological Parents with Myopia 1	24 Participants n=62 Participants	75 Participants n=187 Participants	51 Participants n=125 Participants
Number of Biological Parents with Myopia 2	20 Participants n=62 Participants	72 Participants n=187 Participants	52 Participants n=125 Participants
Number of Biological Parents with Myopia Myopia history unknown for one or both parents	7 Participants n=62 Participants	13 Participants n=187 Participants	6 Participants n=125 Participants
Current Refractive Correction (Single-vision Spectacles or Contact Lenses) Yes	61 Participants n=62 Participants	186 Participants n=187 Participants	125 Participants n=125 Participants
Current Refractive Correction (Single-vision Spectacles or Contact Lenses) No	1 Participants n=62 Participants	1 Participants n=187 Participants	0 Participants n=125 Participants
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes) <-0.2 logMAR	1 Participants n=62 Participants	1 Participants n=187 Participants	0 Participants n=125 Participants
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes) -0.2 to < -0.1 logMAR	5 Participants n=62 Participants	23 Participants n=187 Participants	18 Participants n=125 Participants
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes) -0.1 to < 0.0 logMAR	35 Participants n=62 Participants	97 Participants n=187 Participants	62 Participants n=125 Participants
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes) 0.0 to < 0.1 logMAR	16 Participants n=62 Participants	52 Participants n=187 Participants	36 Participants n=125 Participants
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes) 0.1 to < 0.2 logMAR	5 Participants n=62 Participants	14 Participants n=187 Participants	9 Participants n=125 Participants
Mean OD and OS Flat Corneal Radius	43.6 Diopters squared STANDARD_DEVIATION 1.4 • n=61 Participants • Flat corneal radius was not available for 1 patient in the placebo group.	43.4 Diopters squared STANDARD_DEVIATION 1.4 • n=186 Participants • Flat corneal radius was not available for 1 patient in the placebo group.	43.4 Diopters squared STANDARD_DEVIATION 1.4 • n=125 Participants • Flat corneal radius was not available for 1 patient in the placebo group.
Mean OD and OS Anterior Chamber Depth	3.9 millimeter STANDARD_DEVIATION 0.2 • n=62 Participants	3.9 millimeter STANDARD_DEVIATION 0.2 • n=187 Participants	3.8 millimeter STANDARD_DEVIATION 0.2 • n=125 Participants
Mean OD and OS Lens Thickness	3.3 millimeters cubed STANDARD_DEVIATION 0.2 • n=35 Participants • Lens thickness was not available for some patients (N=53 in atropine and N=27 in placebo) because the biometer used did not provide a lens thickness reading due to measurement difficulty.	3.3 millimeters cubed STANDARD_DEVIATION 0.2 • n=107 Participants • Lens thickness was not available for some patients (N=53 in atropine and N=27 in placebo) because the biometer used did not provide a lens thickness reading due to measurement difficulty.	3.4 millimeters cubed STANDARD_DEVIATION 0.2 • n=72 Participants • Lens thickness was not available for some patients (N=53 in atropine and N=27 in placebo) because the biometer used did not provide a lens thickness reading due to measurement difficulty.

PRIMARY outcome

Timeframe: At 24 months

Outcome measures

Outcome measures
Measure	Atropine Group n=119 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=58 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >0 Diopters	2 Participants	4 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. <=-3.50 Diopters	0 Participants	0 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-3.50 to -3.00 Diopters	1 Participants	0 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-3.00 to -2.50 Diopters	1 Participants	0 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-2.50 to -2.00 Diopters	5 Participants	2 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-2.00 to -1.50 Diopters	8 Participants	7 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-1.50 to -1.00 Diopters	19 Participants	9 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-1.00 to -0.50 Diopters	37 Participants	18 Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. >-0.50 to 0.00 Diopters	46 Participants	18 Participants

PRIMARY outcome

Timeframe: at 24 months

Population: 13 participants were ineligible for randomization, and 10 participants did not complete the 24-month visit.

NIH-required analysis. Primary outcome measure (stratified by sex): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Outcome measures

Outcome measures
Measure	Atropine Group n=119 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=58 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Primary Outcome Measure Stratified by Sex Female	-0.74 Diopters Standard Deviation 0.57	-0.74 Diopters Standard Deviation 0.70
Primary Outcome Measure Stratified by Sex Male	-0.84 Diopters Standard Deviation 0.70	-0.75 Diopters Standard Deviation 0.44

PRIMARY outcome

Timeframe: by 24 months

Population: 13 participants were ineligible for randomization, and 10 participants did not complete the 24-month visit.

NIH-required analysis. Primary outcome measure (stratified by race): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Outcome measures

Outcome measures
Measure	Atropine Group n=119 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=58 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Primary Outcome Measure Stratified by Race More than one race	-0.84 Diopter Standard Deviation 0.68	-0.61 Diopter Standard Deviation 0.58
Primary Outcome Measure Stratified by Race White	-0.67 Diopter Standard Deviation 0.55	-0.74 Diopter Standard Deviation 0.52
Primary Outcome Measure Stratified by Race Black/African American	-0.84 Diopter Standard Deviation 0.63	-1.07 Diopter Standard Deviation 0.74
Primary Outcome Measure Stratified by Race Asian	-1.18 Diopter Standard Deviation 0.80	-0.26 Diopter Standard Deviation 0.51
Primary Outcome Measure Stratified by Race Unknown/not reported	-0.10 Diopter	—

PRIMARY outcome

Timeframe: at 24 months

Population: 13 participants were ineligible for randomization, and 10 participants did not complete the 24-month visit.

NIH-required analysis. Primary outcome measure (stratified by ethnicity): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Outcome measures

Outcome measures
Measure	Atropine Group n=119 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=58 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Primary Outcome Measure Stratified by Ethnicity Not Hispanic or Latino	-0.81 Diopters Standard Deviation 0.66	-0.78 Diopters Standard Deviation 0.62
Primary Outcome Measure Stratified by Ethnicity Hispanic or Latino	-0.63 Diopters Standard Deviation 0.44	-0.54 Diopters Standard Deviation 0.42

PRIMARY outcome

Timeframe: 24 months

The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.

Outcome measures

Outcome measures
Measure	Atropine Group n=119 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=58 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months	-3.64 diopters Standard Deviation 1.46	-3.54 diopters Standard Deviation 1.08

SECONDARY outcome

Timeframe: At 30 months

Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.

Outcome measures

Outcome measures
Measure	Atropine Group n=118 Participants 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=57 Participants Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent <=-3.50 Diopters	1 Participants	0 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-3.50 to -3.00 Diopters	2 Participants	1 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-2.00 to -1.50 Diopters	8 Participants	6 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-0.50 to 0.00 Diopters	36 Participants	13 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >0 Diopters	4 Participants	3 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-3.00 to -2.50 Diopters	5 Participants	0 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-2.50 to -2.00 Diopters	5 Participants	3 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-1.50 to -1.00 Diopters	22 Participants	11 Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent >-1.00 to -0.50 Diopters	35 Participants	20 Participants

Adverse Events

Atropine Group

Serious events: 2 serious events

Other events: 109 other events

Deaths: 0 deaths

Placebo Group

Serious events: 0 serious events

Other events: 56 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Atropine Group n=125 participants at risk 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=62 participants at risk Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
General disorders Hospitalization	1.6% 2/125 • Number of events 2 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.

Other adverse events

Additional Information

Raymond Kraker, PEDIG Coordinating Center Director

Jaeb Center for Health Research

Phone: 8139758690

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Measure	Atropine Group n=125 participants at risk 0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops Atropine: Daily 0.01% atropine eyedrops	Placebo Group n=62 participants at risk Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops Placebo Eyedrops: Daily placebo eyedrops
Eye disorders Visual Impairment	4.8% 6/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	3.2% 2/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Blepharitis	4.8% 6/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Meibomian gland dysfunction	2.4% 3/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	4.8% 3/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Eye Pain	7.2% 9/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Dry Eye	2.4% 3/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Hordeolum	1.6% 2/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	3.2% 2/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Accommodation Disorder	2.4% 3/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Optic Disc Drusen	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Headache	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Visual Acuity Reduced	1.6% 2/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Vitreous Floaters	1.6% 2/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Eye injury	0.00% 0/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	3.2% 2/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Ocular hyperaemia	1.6% 2/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Retinal degeneration	1.6% 2/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Ulcerative keratitis	0.00% 0/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Foreign body in eye	0.00% 0/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Meibomianitis	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Conjunctival hyperaemia	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Dermatitis contact	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Diplopia	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Pruritus	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Lacrimation increased	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Conjunctivitis	0.00% 0/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Chalazion	0.00% 0/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	1.6% 1/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Mydriasis	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Corneal Scar	0.80% 1/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	0.00% 0/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Eye Irritiation	72.0% 90/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	82.3% 51/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Photophobia	25.6% 32/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	27.4% 17/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Vision Blurred	13.6% 17/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	16.1% 10/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Allergic Conjunctivitis	8.0% 10/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	8.1% 5/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.
Eye disorders Ocular Discomfort	6.4% 8/125 • Adverse event data was collected for the duration of the study, baseline to 30 months.	8.1% 5/62 • Adverse event data was collected for the duration of the study, baseline to 30 months.